Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, how much has been spent by each clinical commissioning group in England on Docetaxel since the publication of Docetaxel in combination with androgen deprivation therapy for the treatment of hormone naive metastatic prostate cancer by NHS England on 20 January 2016.
There were no prescriptions of docetaxel by clinical commissioning groups in primary care over this period.
NHS Digital is unable to identify the specific indication for which a prescription has been prescribed. Information on hospital costs (at list price) covering all possible uses is available at NHS England Region level and is provided in the table below:
National Health Service estimated costs (£) of docetaxel (at list price) issued by hospital pharmacies in England1, by region, 2015 and 2016
| 2015 | 2016 |
England1 | 64,346,509 | 71,385,551 |
Central Midlands | 4,681,236 | 5,933,700 |
Cheshire and Merseyside | 4,725,933 | 4,126,694 |
Cumbria and North East | 3,020,396 | 3,571,486 |
East | 5,375,050 | 5,603,733 |
Greater Manchester | 3,349,575 | 2,833,002 |
Lancashire | 1,528,395 | 1,718,229 |
London | 8,746,042 | 10,175,348 |
North Midlands | 4,125,206 | 5,538,382 |
South Central | 3,269,040 | 4,113,010 |
South East | 6,448,259 | 6,182,164 |
South West | 3,924,561 | 4,038,755 |
Wessex | 3,325,580 | 4,016,453 |
West Midlands | 5,432,613 | 6,522,771 |
Yorkshire and Humber | 5,825,101 | 6,429,341 |
Source: 2017 QuintilesIMS: Hospital Pharmacy Audit Index;
Note:
1National figures are grossed up to give England level estimates. Sub-national figures are not adjusted in any way. Therefore, the sum of the regions will not match the England total.